Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 20

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 20
---
 under the listing rules of NASDAQ.

Additional Information

For additional information
related to our business and operations, please refer to the reports incorporated herein by reference, including our Annual Report on Form
20-F for the year ended December 31, 2024, as filed with the SEC on April 11, 2025, and our Reports on Form 6-K, as filed with the SEC,
as described in the section titled “Incorporation of Certain Information by Reference.”

| 8 |

The Offering The following summary contains basic terms about this offering and the securities and is not intended to be complete. It may not contain all of the information that is important to you. You should read the more detailed information contained in this prospectus, including but not limited to, the risk factors beginning on page 14. For a more complete description of the terms of the securities, see the section of this prospectus entitled “Description of the Securities.”

| Securities offered by us |     | Up to 3,377,110 Units, each Unit consisting                                                                                              
 of one Depositary Share and one Series L Warrant to purchase one Depositary Share for cash or otherwise acquire such greater number of   
 Depositary Shares as determined in accordance with the provisions of the Series L Warrant upon a zero cash exercise price option.        
 This prospectus also relates to the offering of the Depositary                                                                           
 Shares issuable upon exercise of the Series L Warrants and Pre-Funded Warrants. To better understand the terms of the Series L Warrants, 
 you should carefully read the “Description of the Securities We Are Offering” section of this prospectus. You should                     
 also read the form of the Series L Warrant and Pre-Funded Warrant, which is filed as an exhibit to the registration statement of which   
 this prospectus forms a part.                                                                                                            |

| 9 |

|                                |     | We are also offering to investors in Units that would otherwise                                                                                  
 result in the investor’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, up to 9.99%) of our outstanding             
 Ordinary Shares immediately following the consummation of this offering the opportunity to invest in units consisting of one Pre-Funded          
 Warrant to purchase one Depositary Share in lieu of one Depositary Share and one Series L Warrant. Subject to limited exceptions, a holder       
 of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if the holder,